Sophia S. Li , Robert Schuldt , Faiza Zafar , Tu My To , Archibong Yellow-Duke , Alina Levine , Allicia Girvan , Shelli Spence , Joseph Mikhael
{"title":"社会经济地位和医疗资源可获得性对老年(≥66岁)非西班牙裔黑人与非西班牙裔白人多发性骨髓瘤患者生存的影响","authors":"Sophia S. Li , Robert Schuldt , Faiza Zafar , Tu My To , Archibong Yellow-Duke , Alina Levine , Allicia Girvan , Shelli Spence , Joseph Mikhael","doi":"10.1016/j.clml.2024.11.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Several factors contribute to the known disparities in overall survival (OS) between non-Hispanic Black (NHB) patients and non-Hispanic White (NHW) patients with multiple myeloma (MM).</div></div><div><h3>Patients and Methods</h3><div>To explore whether socioeconomic status (SES) and healthcare resource (HCR) availability impacts OS, this retrospective study used linked Surveillance, Epidemiology, and End Results (SEER)-Medicare claims and Area Health Resource Files to identify NHB and NHW patients aged ≥66 years with MM (newly diagnosed 6/1/2013-12/31/2017). Continuous Medicare A and B enrollment until 12/31/2019 or preceding death was required.</div></div><div><h3>Results</h3><div>In total, 6,609 patients were identified; 15.6% were NHB. At baseline, NHB patients were younger, more likely to be female, had higher Charlson Comorbidity Index (CCI), and were more likely to live in census tracts with lower education attainment and higher poverty percentages than NHW patients.</div><div>Unadjusted median OS by race/ethnicity for NHB patients versus NHW patients was 2.76 versus 3.01 years (hazard ratio [HR]: 1.08; <em>P</em> = .063). In the adjusted model, older age at diagnosis (<em>P</em> < .001), male sex (<em>P</em> = .02), and higher CCI (<em>P</em> < .001) increased risk of death. Poverty (<em>P</em> = .02) and number of active medical doctors per 100,000 (<em>P</em> = .003) were significant but not clinically meaningful. OS HR by race reversed directionality when adjusted for demographics, SES and HCR availability (HR: 0.92; <em>P</em> = .12).</div></div><div><h3>Conclusion</h3><div>Several factors, including SES and HCR availability, significantly influenced OS and may drive disparities in care for patients with MM. Further research on larger datasets is needed.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 4","pages":"Pages 285-292.e1"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple Myeloma\",\"authors\":\"Sophia S. Li , Robert Schuldt , Faiza Zafar , Tu My To , Archibong Yellow-Duke , Alina Levine , Allicia Girvan , Shelli Spence , Joseph Mikhael\",\"doi\":\"10.1016/j.clml.2024.11.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Several factors contribute to the known disparities in overall survival (OS) between non-Hispanic Black (NHB) patients and non-Hispanic White (NHW) patients with multiple myeloma (MM).</div></div><div><h3>Patients and Methods</h3><div>To explore whether socioeconomic status (SES) and healthcare resource (HCR) availability impacts OS, this retrospective study used linked Surveillance, Epidemiology, and End Results (SEER)-Medicare claims and Area Health Resource Files to identify NHB and NHW patients aged ≥66 years with MM (newly diagnosed 6/1/2013-12/31/2017). Continuous Medicare A and B enrollment until 12/31/2019 or preceding death was required.</div></div><div><h3>Results</h3><div>In total, 6,609 patients were identified; 15.6% were NHB. At baseline, NHB patients were younger, more likely to be female, had higher Charlson Comorbidity Index (CCI), and were more likely to live in census tracts with lower education attainment and higher poverty percentages than NHW patients.</div><div>Unadjusted median OS by race/ethnicity for NHB patients versus NHW patients was 2.76 versus 3.01 years (hazard ratio [HR]: 1.08; <em>P</em> = .063). In the adjusted model, older age at diagnosis (<em>P</em> < .001), male sex (<em>P</em> = .02), and higher CCI (<em>P</em> < .001) increased risk of death. Poverty (<em>P</em> = .02) and number of active medical doctors per 100,000 (<em>P</em> = .003) were significant but not clinically meaningful. OS HR by race reversed directionality when adjusted for demographics, SES and HCR availability (HR: 0.92; <em>P</em> = .12).</div></div><div><h3>Conclusion</h3><div>Several factors, including SES and HCR availability, significantly influenced OS and may drive disparities in care for patients with MM. Further research on larger datasets is needed.</div></div>\",\"PeriodicalId\":10348,\"journal\":{\"name\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"volume\":\"25 4\",\"pages\":\"Pages 285-292.e1\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2152265024024212\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024024212","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple Myeloma
Background
Several factors contribute to the known disparities in overall survival (OS) between non-Hispanic Black (NHB) patients and non-Hispanic White (NHW) patients with multiple myeloma (MM).
Patients and Methods
To explore whether socioeconomic status (SES) and healthcare resource (HCR) availability impacts OS, this retrospective study used linked Surveillance, Epidemiology, and End Results (SEER)-Medicare claims and Area Health Resource Files to identify NHB and NHW patients aged ≥66 years with MM (newly diagnosed 6/1/2013-12/31/2017). Continuous Medicare A and B enrollment until 12/31/2019 or preceding death was required.
Results
In total, 6,609 patients were identified; 15.6% were NHB. At baseline, NHB patients were younger, more likely to be female, had higher Charlson Comorbidity Index (CCI), and were more likely to live in census tracts with lower education attainment and higher poverty percentages than NHW patients.
Unadjusted median OS by race/ethnicity for NHB patients versus NHW patients was 2.76 versus 3.01 years (hazard ratio [HR]: 1.08; P = .063). In the adjusted model, older age at diagnosis (P < .001), male sex (P = .02), and higher CCI (P < .001) increased risk of death. Poverty (P = .02) and number of active medical doctors per 100,000 (P = .003) were significant but not clinically meaningful. OS HR by race reversed directionality when adjusted for demographics, SES and HCR availability (HR: 0.92; P = .12).
Conclusion
Several factors, including SES and HCR availability, significantly influenced OS and may drive disparities in care for patients with MM. Further research on larger datasets is needed.
期刊介绍:
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.